Vitasora Health (VHL) investor relations material

Growth strategy and market opportunity

• Leadership team with deep US healthcare experience is driving a scalable platform and a patient list of ~40,000, accelerating revenue growth and a clear path to breakeven by September 2025.

• Fee-for-service (FFS) programs are the main revenue driver, now accounting for 72% of revenue, with monthly FFS revenue reaching ~$190K in May and total estimated monthly revenue at ~$275K.

• The US remote patient monitoring (RPM) market is forecast to reach $6.3B–$29.1B by 2030, with only 3% of eligible Medicare patients currently using CCM and less than 1% using RPM, leaving a large untapped market.

• Regulatory changes in 2026 will lower RPM billing thresholds, introduce new codes, and increase CCM rates by 8%, expanding addressable revenue per patient.

• Embedded growth opportunities exist within existing clients, with no new client acquisition needed to reach breakeven.

Operating performance and financials

• FFS billings increased 63% from September 2025 to May 2026, with record daily revenue of ~$9,500 in May (+72% YoY).

• Revenue yield per billed patient rose 35% to $67, and CPT codes per patient increased 22% to 1.90, with targets of 2.5 by September and 3.0 by year-end.

• Active patient volumes grew 43.8% and enrolled programs 38.1% over nine months, with onboarding volumes doubling in two months post-vCare rollout.

• Cost transformation initiatives reduced monthly OpEx by 29% to $591K, with further SaaS and IT savings expected.

• LTV/CAC ratio stands at 6.0x, with a 10-month payback period, supporting efficient scaling.

Outlook and investment highlights

• Three revenue lines (FFS, UPEC, TCM) are driving recurring revenue, with FFS revenue projected to reach $250K in June and dual RPM enrolment expected to hit 50% by September.

• Base case revenue is forecast to reach $1.4M/month by mid-2027, with an optimistic scenario of $2.2M/month and a target EBITDA margin of 20% by Q2 2027.

• Private placement of A$1.5M is underway to fund patient management, sales, vCare enhancement, and working capital.

• Non-dilutive debt financing facilities are being pursued to enhance liquidity and support growth.

• The executive team brings extensive US healthcare, technology, and operational expertise, supporting the company’s growth and scalability.